-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $394

Benzinga·02/04/2026 13:58:16
Listen to the news
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $385 to $394.